Smoking Promotes Subclinical Atherosclerosis
this reduction, we evaluated the associations of MetS parameters as well as inflammatory markers with IMT and their relationship with smoking habit in drug-naїve apparently healthy subjects.
Methods

Subjects
The subjects were the men who underwent health examinations in the Osaka University Health Care Center during [2005] [2006] [2007] . Apparently healthy Japanese men (n=354), 40-59 years of age, who completed an annual visit for medical checkup in 3 consecutive years, did not take any chronic or frequent medicine from at least 1 year before the first visit to the end of followup, did not suffer acute illness within 2 weeks before each visit and successfully underwent carotid ultrasonography in the first and the third visits were consecutively included. Informed consent was obtained from all subjects prior to participation in the study following approval of the study by the Ethics Committee of Osaka University. Because blood tests for hs-CRP, IL-6, and adiponectin concentration were beyond routine annual medical checkup, these tests were also performed in samples from 89 men (42/29/18 in never, past and current smokers, respectively) who participated in this study and who also agreed in writing to additional investigational measurements.
Definition of Past Smoker and Smoking Cessation Period
Smoking habit for each participant was primarily obtained from the mark in the check boxes sorting them into never, current or past smokers, as well as complementary descriptions determining the duration of smoking period in the interview sheet at annual medical checkup. For the past smokers, because the smoking cessation periods were not directly queried on the interview sheet, all the past interview sheet records for each individual were surveyed and the duration of smoking cessation defined as the period starting from the first year after the smoking habit changed from current to past smoker. If it was the case that all the past records indicated past smoking habit or the record was not available, we then referred to a formula of [(Age, years old) -(duration of smoking period, years) -20] year(s), based on the directly acquired data via the interview, to estimate the smoking cessation period.
Risk Factor Assessment
Information on medical history, use of medicines and personal smoking habit were obtained via questionnaire, and was reconfirmed in expert interview by trained nurses. Waist circumference at the umbilical level was measured in the late exhalation phase in standing position.
Laboratory Measurements
Serum was collected from subjects after overnight fasting and kept at ≤-20°C until assay. Serum hs-CRP, IL-6 and adipo- nectin concentration were measured as described previously. 14,15 Briefly, they were measured using an immunoenzyme assay, a chemiluminescent enzyme immunoassay (CLEIA) and a sandwich enzyme-linked immunosorbent assay (ELISA) system, respectively. The mean interclass coefficient of variation (CV) of hs-CRP, IL-6, and adiponectin measurements (n=40) in the assays before this study were 1.1%, 4.5%, and 1.2%, respectively. Kits from the same lots were used in this study to maintain reliability of measurement.
Evaluation of Carotid Atherosclerosis
All ultrasound examinations were performed by a single welltrained sonographer (K.I.) who regularly participated in quality control measurement sessions and was totally blinded to all clinical information, using LOGIQ 5 (GE Yokogawa Medical Systems, Tokyo, Japan) with an 8.8-MHz linear transducer. Three different longitudinal images (anterior oblique, lateral, and posterior oblique) of the left common carotid artery (CAA) of a 1.0-1.5-cm section at the distal end of the CCA proximal to the carotid bulb were obtained as described previously, 14,15 complying with validated protocols. In addition, transverse images were then obtained to confirm the accuracy of longitudinal images. After examination, the best longitudinal images were analyzed for each individual. Maximum and mean IMT was obtained using computer software that automatically traces the intima-media edge of the far wall. The presence of plaque was defined as detection of a focal structure encroaching into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT or having a thickness of ≥1.5 mm, in concordance with a previous report. 16 
Statistical Analysis
Data were analyzed using SPSS 14.0 (Chicago, IL, USA). Pearson's correlation coefficients were calculated for variables with skewed distribution after logarithmic transformation. Stepwise multiple regression analysis was conducted using the enter method. ANOVA with modified Bonferroni's post-hoc test was used to assess differences between groups based on category. In order to analyze correlation of smoking with the progression of IMT, current, past and never smokers were scored as 1, 0.5 and 0, respectively, and the sum of this score was used, together with IMT progression within 2 years in each individual. P<0.05 was considered statistically significant.
Results
Baseline Demographics
Clinical characteristics of the study subjects are summarized in Table 1 . With regard to risk factors, age was significantly older, and waist circumference and serum triglyceride (TG) level significantly higher as smoking habit progressed in men, whereas no significant differences were seen in body mass index (BMI), blood pressure (BP), uric acid (UA), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG) and HbA1c. As shown in Table 1 , both maximum and mean IMT tended to increase as smoking habit progressed, reaching significance in mean IMT. Plaques as defined in a previous report 16 were Figure 1 . Changes in maximum and mean intima-media thickness (IMT) from baseline to 2 years follow-up in all subjects. Data given as mean ± SD. ***P<0.0001 vs. baseline. Table 2 . Current smokers were liable to have a longer smoking history, but there was no significant change in the number of cigarettes, and there were very few heavy smokers consuming >40 cigarettes per day in each group.
Progression of IMT During Follow-up and Association With MetS Components
After 2 years of follow-up, both maximum and mean IMT in all subjects significantly increased (P<0.0001) compared with baseline ( Figure 1) . Single regression analysis between the traditional risk factors and the change in IMT (delta-IMT) from before to after 2 years follow-up is given in Table 3 . Among them, systolic BP, serum TG, LDL-C and HbA1c as well as smoking habit were significantly correlated with delta-maximum IMT, whereas serum UA correlated only with delta-mean IMT, and serum LDL-C as well as HbA1c were associated with both parameters. In contrast, age, BMI, waist circumference, diastolic BP, HDL-C and FPG were not correlated with delta-IMT. Figure 2 charts delta-IMT during 2 years follow-up along with smoking habit (never, past and current smoker). Current smoking was associated with a tendency for increase in both delta-maximum and delta-mean IMT, which was significant in delta-maximum IMT. Past smokers tended to have less of an increase, and this did not reach significance. Among the aforedescribed MetS parameters as well as smoking habit, stepwise regression analysis (Table 4) showed that only smoking habit and serum LDL-C were significantly correlated with delta-maximum IMT, suggesting that these 2 parameters would be independent contributors for increased progression of atherosclerosis. Furthermore, to clarify whether MetS components had changed during the 2-year observation period, we additionally evaluated the relationship between IMT and the mean of the (Table S1 ). We observed that only mean LDL-C during 2 years of follow-up had a significant association with progression of both maximum and mean IMT, further suggesting the important contribution of LDL-C to the progression of atherosclerosis. As to period of smoking cessation, longer estimated cessation >10 years tended to provide further moderation of progression of delta-maximum IMT (Figure 3) , but was not significant (P=0.1139 and 0.534 in maximum and mean IMT, respectively). We then further investigated the association of atherosclerosis progression with either smoking or smoking cessation period, and found that positive correlation with smoking period might be stronger than the negative correlation with smoking cessation period among past smokers, although not significant (Table S2) .
Change in IMT During Follow-up and Association With Smoking Habit
2-year blood test results
Smoking Habit, Serum IL-6, Adiponectin and hs-CRP To further elucidate the underlying mechanisms, serum IL-6, adiponectin, and hs-CRP at baseline were evaluated. As shown in Figure 4 , serum IL-6 and hs-CRP at baseline were significantly higher in current smokers (1.22±0.53 pg/ml and 0.63± 0.65 mg/L, respectively), compared with never and past smokers. Serum adiponectin tended to be higher in never smokers than past and current smokers, but no significant difference was observed. Furthermore, we found that IL-6 and hs-CRP had a significant positive correlation with the duration of smoking, and hs-CRP also had a significant negative correlation with duration of smoking cessation among past smokers (Table S3) . Taken together, moderated progression of subclinical atherosclerosis was achieved in past smokers compared to current smokers, associated with complete reversal of inflammatory activation. This implies that smoking cessation and associated inflammatory deactivation might be another critical factor for inhibiting accelerated progression of subclinical atherosclerosis in addition to LDL-C lowering in men.
Discussion
In the present group of apparently healthy men we found that atherosclerosis, as evaluated via carotid IMT, significantly progressed, and was independently and significantly accelerated as serum LDL-C increased and as smoking habit progressed, as shown on multiple regression analysis. Serum hs-CRP and IL-6 were significantly higher in only current smokers, but in past smokers were completely the same as in never smokers. Many previous studies have reported that smoking is a major promoter of atherosclerotic change, 17 and that cessation of smoking is strongly recommended, and is associated with possible reduction of risk for CVD. 18,19 Direct and quantitative evaluation of the impact of smoking cessation on long-term atherosclerotic change, however, was still to be documented. Here, in the present study, we have carried out a prospective 2-year follow-up of IMT changes in apparently healthy men. This had been done only in 1 previous report in healthy men/ women, 19 which primarily supported the present findings of incomplete recovery from accelerated mean IMT increase after 2 years. The direct mechanistic linkage underlying smoking cessation and atherosclerotic progression, however, had not been investigated.
For the first time, we analyzed IMT change over time along with smoking habit, MetS status and multiple inflammatory parameters. We evaluated 89 samples from participants who agreed to additional blood sampling in writing, and on analysis of direct correlation between IL-6, hs-CRP and IMT, IL-6 had P=0.054 for positive correlation, whereas CRP did not have any association with IMT. Accordingly, our previous report evaluated this issue in a similar cohort of 153 apparently healthy men, and successfully observed the identical tendency. 15 Briefly, IL-6 was significantly correlated with either delta-maximum (P=0.02) or delta-mean (P=0.008) IMT, whereas the hs-CRP correlation was not significant (P=0.24 in delta-maximum delta-mean IMT) . Therefore, we could assume that the inflammatory status represented by serum IL-6 potentially affects IMT progression. Although the NHANES III study (15,489 individuals) showed that blood CRP returned to baseline 5 years after smoking cessation, 20 which is consistent with the time frame associated with cardiovascular risk reduction observed in both the MONICA and Northwick Park Heart studies, 20-22 we intriguingly obtained the novel finding that the past smokers do not achieve complete recovery from accelerated increase in both maximum and mean IMT, despite complete reversal of inflammatory status after the shorter period of 2 years. This time frame-dependent dissociation might be explained in some way by the different characteristics and size of the subject group, but it may also be due to another longlasting producer of IMT progression other than inflammatory status, that is, smoking. In this way, the underlying mechanisms of preclinical IMT progression and clinically relevant CVD incidence, as well as the markers representing the respective risks, should be somewhat different. Accordingly, regression analysis of the relationship between atherosclerosis progression and the duration of either smoking or smoking cessation period (Tables S2,3) showed that maximum-IMT had a stronger positive correlation with the duration of smoking period than negative correlation with the duration of smoking cessation period in past smokers, further supporting this idea. This might ultimately lead to the idea that interventions to avoid smoking from the beginning might be as important as those to stop smoking.
Because the inflammatory response is widely recognized as an independent risk factor for CVD, 1,5 and is reported to be closely associated with vulnerable plaque, 23 we can say that smoking cessation rapidly reduces the vulnerability of atherosclerotic regions via inflammatory inactivation, whereas more time, or even years, would be needed to reverse the acceleration of primary atherosclerotic progress represented by increased IMT due to other mechanisms. Accordingly, the Heinz Nixdorf Recall Study of 4,814 individuals without overt CHD also showed that the growth of the coronary atherosclerotic region is accelerated by smoking and slows down after smoking cessation, but advanced atherosclerotic change is present for a long period. 24 The question then arises as to what other mechanism than inflammatory response may be responsible for the prolonged IMT progression.
In this study the annual increase of mean IMT was around 0.030-0.050 mm, which might be greater than that reported in the many previous studies on the progression of IMT in healthy subjects. There are some reports, however, indicating that the progression of mean IMT in asymptomatic young adults varies from 0.015 to 0.029 mm/year. 25 Furthermore, we collected the present data from untreated and middle-aged individuals, who might be substantially more susceptible to IMT progression. 26 Taken together, we could say that the current data regarding the annual increase of mean IMT of around 0.030-0.050 mm might be within reasonable range.
As a possible mechanism, Oyama et al showed that green tea catechins have anti-atherosclerotic properties among smokers by increasing the level of nitric oxide and reducing oxidative stress. 27 In contrast, it is widely accepted that the impairment of MetS status substantially promotes the progression of atherosclerosis 28 and increases the risk of CVD. 1 Also, another study on a cohort of 5,033 individuals with the same characteristics as the present subjects suggested that the exposure to MetS would explain at least in part the increasing risk of excessive carotid plaque in past smokers. 29 The present result from stepwise regression analysis also showed that serum LDL-C level and smoking habit were the only independent predictors of IMT progression. This result is primarily supported by a previous study in a cohort of 2,421individuals who have similar characteristics with the present subjects followed up for 14 years. 30 According to Table 1 , however, past smokers have normal MetS parameters including BMI, waist circumference, BP, UA, TG, LDL-C and HDL-C and HbA1c, which are equal to those of never smokers. This is possibly in part due to the relatively small size of the data set, because the data in Table 2 differ from those in previous reports that suggested waist circumference 31 or HDL-C 32 as independent risk factors for accelerated atherosclerosis. Accordingly, the JART study in the same ethnic population showed that intensive lipid-lowering treatment with rosuvastatin effectively eliminated the progression of IMT compared with pravastatin treatment, and was associated with a much higher rate of achieving lower LDL-C/ HDL-C ratio <1.5. 33 The present cohort had a mean LDL-C level within normal limits but a relatively higher LDL-C/HDL-C ratio (2.373±0.056 for never, 2.390±0.089 for past and 2.496±0.109 for current smokers, respectively, P=0.55), suggesting that more intensive lipid-lowering strategy beyond normalizing LDL-C level might facilitate the reduction of atherosclerosis progression. Otherwise, the present results might downgrade the relative importance of impaired MetS status including hypercholesterolemia as a putative promoter of smoking-induced prolonged atherosclerotic progression. The only difference we observed in past smokers compared with never smokers was a trend toward lower blood adiponectin level, which was almost identical to that of current smokers. Adiponectin is an adipocytokine mainly secreted from visceral fat tissues, 34 and the reduction of its blood level is reported to be an independent risk factor for atherosclerotic progression. 35 Although the duration for recovery of blood adiponectin level after smoking cessation is currently elusive, varying from 2 months to up to 20 years in men, 36,37 complete recovery from accelerated peripheral arterial atherosclerosis due to smoking represented by impaired ankle-brachial index will take up to 20 years after smoking cessation. 38 Experimental studies show that adiponectin has a direct cardioprotective property, 35 therefore adiponectin could be a potential contributor to smoking-induced prolonged atherosclerotic progression. Accordingly, Table S3 suggests a potential inverse correlation of adiponectin level with smoking habit: decreasing with intensity and length of smoking ands increasing with the duration of smoking cessation, but it is possible that the 2-year follow-up period was too short to evaluate the long-term effect of adiponectin. This issue should be directly addressed by further study with an increased number of participants.
As a limitation, because smoking habit was confirmed only by questionnaire and interview, we cannot exclude the possibility that some of the past smokers were occasionally exposed to temporary smoking episodes during follow-up. Also, we did not follow the subjects for a longer period because of the study design. Furthermore, we did not measure luminal diameter routinely in this study. The primary aim of IMT measurement was to study the surrogate marker of atherosclerotic change in normal or preclinical stages. The core requirement to achieve this goal was to measure the initial and small changes of maximum and mean IMT precisely in a large cohort. To achieve this, we ensured that a well-trained and established sonographer performed the entire IMT test himself, to avoid inter-individual variance. This meant that it was necessary to limit the list of measurements to scoring of maximum and mean IMT, accompanied by informal observation of visually advanced narrowing, because IMT measurements were SANADA S et al.
performed on approximately 5,000 candidates and applicants every year, along with the institutional annual general medical checkup.
In addition, we could not measure the inflammatory markers (IL-6, adiponectin and hs-CRP) repeatedly because written informed consent limited the measurements to once only, at the time of entry.
Finally, we can conclude that subclinical atherosclerosis is independently accelerated via continuous smoking or LDL-C, and that the smoking-induced promotion of atherosclerotic change is closely associated with inflammatory reactions. Furthermore, the entire inhibition of activated inflammatory responses by smoking cessation is still insufficient to abrogate accelerated progression of subclinical atherosclerosis after 2 years in men, and reduced adiponectin level can be potentially proposed as an underlying mediator. Further investigation into the role of adiponectin in relation to smoking cessation in a larger cohort for a longer period is therefore warranted, to enable investigation of a direct mechanistic link between them, and to verify strategies to increase adiponectin as a therapeutic intervention against atherosclerosis and subsequent CVD events.
